AlphaCentric Advisors’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$216K Buy
+10,480
New +$224K 0.19% 143
2024
Q4
– Sell
-15,000
Closed -$341K – 285
2024
Q3
$341K Buy
15,000
+2,500
+20% +$40.9K 0.25% 102
2024
Q2
$163K Buy
12,500
+6,500
+108% +$90K 0.12% 137
2024
Q1
$105K Buy
+6,000
New +$116K 0.06% 186
2023
Q4
– Sell
-80,000
Closed -$1.23M – 286
2023
Q3
$1.23M Buy
80,000
+44,500
+125% +$849K 0.7% 47
2023
Q2
$845K Hold
35,500
– – 0.47% 75
2023
Q1
$903K Hold
35,500
– – 0.62% 58
2022
Q4
$1.04M Hold
35,500
– – 1.02% 34
2022
Q3
$728K Buy
+35,500
New +$638K 0.75% 45

Other funds holding VRDN

AlphaCentric Advisors's VRDN Position: Q3 2026 in Review

AlphaCentric Advisors opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 10,480 shares worth $216K. The stake represents 0.19% of the portfolio and ranks #143 among its holdings. This is a return to the name: AlphaCentric Advisors previously reported a position in VRDN as recently as Q3 2024.

AlphaCentric Advisors first reported a position in VRDN in Q3 2022 and has held it in 9 quarters since. The position peaked at $1.23M in Q3 2023. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • AlphaCentric Advisors held 10,480 shares of Viridian Therapeutics worth $216K as of Q3 2026.
  • Viridian Therapeutics was a new AlphaCentric Advisors position in Q3 2026.
  • Viridian Therapeutics made up 0.19% of AlphaCentric Advisors's portfolio in Q3 2026, its #143 holding.
  • AlphaCentric Advisors first reported a position in Viridian Therapeutics in Q3 2022 and has held it in 9 quarters since.
  • AlphaCentric Advisors's Viridian Therapeutics position peaked at $1.23M in Q3 2023.
  • 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.